D-Cycloserine Augmentation of Exposure & Response Prevention Treatment for

Status Withdrawn

Clinical Trial Summary

We propose to undertake an initial study of DCS to determine whether it has any short-term clinical benefits when added to standard ERP therapy in adults with OCD.

Clinical Trial Description

Exposure and response prevention (ERP) has proven efficacy for OCD treatment in adults. Yet, ERP does not help all individuals, and those who benefit often remain somewhat symptomatic. Behavioral models for OCD treatment are based on two components. First, fears are acquired by the development of an association between a neutral stimulus and an aversive stimulus such the former acquires the aversive properties of the latter. The neutral stimulus is then designated as a conditioned stimulus (CS), and the original aversive stimulus is called an unconditioned stimulus (UCS). Second, the acquired fears can be unlearned through presentation of the CS in the absence of the UCS, a process known as extinction. On a neural level, ERP incorporates similar mechanisms to those involved in fear conditioning. Antagonists at the glutamatergic NMDA receptor, which is involved in learning and memory, block both fear learning and extinction. D-Cycloserine (DCS), a partial agonist at the N-methyl-D-aspartate (NMDA) glutamate receptor subtype, augments learning in animals and humans. Clinical application in animals and humans suggest that DCS facilitates the fear extinction process when taken prior to exposure to feared stimuli. An initial trial in acrophobic adults provided support for acute DCS dosing as facilitating extinction to fear. Given that ERP is based on extinction, it follows that DCS may augment ERP therapy providing enhanced treatment effects. With this in mind, we propose to undertake an initial study of DCS to determine whether it has any short-term clinical benefits when added to standard ERP therapy in adults with OCD. ;

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00257361
Study type	Interventional
Source	University of Florida
Contact
Status	Withdrawn
Phase	Phase 2
Start date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04631042` - Developing Brain, Impulsivity and Compulsivity
Completed	`NCT02855580` - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed	`NCT02229903` - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD	N/A
Completed	`NCT02202915` - CBT for Pediatric OCD: Community Training Pilot	N/A
Completed	`NCT01794156` - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder	N/A
Completed	`NCT02089984` - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders	N/A
Completed	`NCT01348529` - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)	N/A
Recruiting	`NCT00965211` - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome	N/A
Not yet recruiting	`NCT00743834` - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)	Phase 4
Completed	`NCT00723060` - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder	Phase 4
Completed	`NCT01172873` - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD	N/A
Completed	`NCT02421315` - Overlapping Neural Circuits in Pediatric OCD	N/A
Completed	`NCT02194075` - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder	Phase 4
Completed	`NCT01981317` - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder	N/A
Completed	`NCT01686087` - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder	N/A
Terminated	`NCT00997087` - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder	Phase 2
Completed	`NCT01331876` - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy	N/A
Completed	`NCT00533806` - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder	Phase 3
Completed	`NCT00517244` - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders	N/A
Completed	`NCT00169377` - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms